...S.A.S., China Medical System Holdings Ltd. (HKEX:867) and Mediolanum...

...Acticor and Mediolanum partnered to develop Acticor’s acute ischemic stroke candidate ACT017 . Mediolanum will co-own...
...acquire marketing rights in two undisclosed European countries. Acticor received an undisclosed upfront payment from Mediolanum...
...inquiries. Acticor Biotech S.A.S., Paris, France Mediolanum Farmaceutici S.p.A. , Milan, Italy Business: Neurology Nora Weintraub ACT-017 Acticor Biotech Mediolanum...

...Panoptes granted Mediolanum rights to market PP-001 in two undisclosed European countries. Panoptes received an undisclosed...
...undisclosed development and sales milestones, plus royalties. Panoptes declined to disclose further financial terms, and Mediolanum...
...DHODH) is in preclinical testing to treat chronic uveitis. Panoptes Pharma GmbH , Vienna, Austria Mediolanum...

...therapy Date completed: 2015-01-23 Type: Venture financing Raised: EUR6.2 million ($7.2 million) Investors: Banca Esperia; Mediolanum...

...trials to treat NSCLC and pancreatic cancer. Kael did not respond to requests for comment. Mediolanum...
...CSE:AFFI), Horsolm, Denmark Genovax s.r.l. , Turin, Italy Kael Co. Ltd. (KOSDAQ:082270), Daejon, South Korea Mediolanum...

...Pharma Mediolanum acquired cancer vaccine GX301 from Genovax. Mediolanum will be responsible for developing and commercializing...
...is in preclinical testing to treat systemic lupus erythematosus (SLE). Genovax s.r.l. , Turin, Italy Mediolanum...

...regulatory and pharmaceutical affairs and head of the nanotechnology business unit, formerly managing director at Mediolanum...